SCHEMBL16057273

SCHEMBL16057273

Cc1c(-c2ccc(C3CCCC3)cc2)ccn(C(=O)O)c1=O

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CYP3A4 P08684 2/20 0.41
▸ CYP2C9 P11712 1/20 0.41
▸ APP P05067 1/20 0.41
▸ S1PR1 P21453 4/20 0.38
▸ DHODH Q02127 2/20 0.38
▸ HDAC1 Q13547 1/20 0.36
▸ HDAC8 Q9BY41 1/20 0.36
▸ HDAC6 Q9UBN7 1/20 0.36
▸ PRKAB2 O43741 1/20 0.36
▸ PRKAG1 P54619 1/20 0.36
▸ PRKAA2 P54646 1/20 0.36
▸ PRKAA1 Q13131 1/20 0.36
▸ PRKAG3 Q9UGI9 1/20 0.36
▸ PRKAG2 Q9UGJ0 1/20 0.36
▸ PRKAB1 Q9Y478 1/20 0.36
▸ KMT2A Q03164 2/20 0.36
▸ TDP1 Q9NUW8 2/20 0.36
▸ HSP90AA1 P07900 1/20 0.36
▸ GAA P10253 1/20 0.36
▸ MAPT P10636 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14977412 0.99 CYP3A4 (0.43) CYP3A4CYP2C9APPS1PR1DHODH
SCHEMBL16057667 0.89 PRKAB2 (0.41) CYP3A4CYP2C9PRKAB2PRKAG1PRKAA2
SCHEMBL14975270 0.79 KDM4E (0.39) CYP2C9KMT2AMAPTKDM4ESMN1; SMN2
SCHEMBL16056640 0.77 PTGS2 (0.40) CYP3A4CYP2C9KMT2AGAAMAPT
SCHEMBL16058690 0.75 S1PR1 (0.40) S1PR1MAPTS1PR5RAB9AKDM4E
SCHEMBL16056811 0.74 HPGD (0.50) KMT2ANPC1RAB9A
SCHEMBL16056980 0.73 NPC1 (0.42) KMT2AGAAMAPTNPC1RAB9A
SCHEMBL16056806 0.73 LMNA (0.41) KMT2ATDP1RAB9AKDM4EHTT
SCHEMBL16058367 0.73 DHODH (0.43) DHODHMAPTNPC1RAB9AACMSD
SCHEMBL14977319 0.73 APP (0.41) APPDHODHMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9828338-B2 Carbamate derivatives of lactam based N-acylethanolamine acid amidase (NAAA) inhibitors THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2017-11-28 — — US disclosed
US-20160068482-A1 CARBAMATE DERIVATIVES OF LACTAM BASED N-ACYLETHANOLAMINE ACID AMIDASE (NAAA) INHIBITORS THE REGENTS OF THE UNIVERSITY OF CALIFORNIA 2016-03-10 — — US disclosed
WO-2014144836-A2 CARBAMATE DERIVATIVES OF LACTAM BASED N-ACYLETHANOLAMINE ACID AMIDASE (NAAA) INHIBITORS THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2014-09-18 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160068482-A1 CARBAMATE DERIVATIVES OF LACTAM BASED N-ACYLETHANOLAMINE ACID AMIDASE (NAAA) INHIBITORS NAAA, FAAH, FAAH2 CYP3A4 1429/4885CYP2C9 1191/4885APP 550/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback